Netazepide

CAS No.	155488-25-8
MDL No.	MFCD00937935
MF	C₂₈H₃₀N₆O₃
MW	498.60
InChI Key	YDZYKNJZCVIKPP-VWLOTQADSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	155488-25-8
Product Name	Netazepide

Biological Targets

CCKBR

Associated Conditions

peptic esophagitis·carcinoid tumor·Barrett's esophagus·Zollinger-Ellison Syndrome·dyspepsia

* The information provided here is compiled from public sources and is for reference only.

Netazepide

CAS No.	155488-25-8
MDL No.	MFCD00937935
MF	C₂₈H₃₀N₆O₃
MW	498.60
InChI Key	YDZYKNJZCVIKPP-VWLOTQADSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	155488-25-8
Product Name	Netazepide

Biological Targets

CCKBR

Associated Conditions

peptic esophagitis·carcinoid tumor·Barrett's esophagus·Zollinger-Ellison Syndrome·dyspepsia

* The information provided here is compiled from public sources and is for reference only.

Netazepide

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Netazepide

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

Netazepide

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.

Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.

Pharmacological analysis of CCK(2) receptor ligands using COS-7 and SK-N-MC cells, expressing the human CCK(2) receptor.

(3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.

Netazepide

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.

Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.

Pharmacological analysis of CCK(2) receptor ligands using COS-7 and SK-N-MC cells, expressing the human CCK(2) receptor.

(3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.

Documentation